ApprovedFDA approval

Ambelvist (gadoquatrane)

Bayer HealthCare

Marketer take

A gadolinium MRI contrast agent entering a commoditized category, so radiology departments and group purchasing decisions matter more than referring physicians.

Sponsor company
Bayer HealthCare
Indication
To detect and visualize lesions with abnormal vascularity, in conjunction with MRI
Therapeutic area
Diagnostic imaging
Event
FDA approval
Date
Jun 12, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move